Piramal Pharma (PPLPHARMA) Share News & Alerts
Every article that mentions PPLPHARMA is analysed by our AI, which assigns a sentiment and tracks the actual price move after the alert fires.
Piramal Pharma Q4 Results: Drugmaker Swings Into Net Loss As One-Time Cost Weighs, Revenue Flat
▼ Bearish +0.46%
The stock is likely to face selling pressure as it missed analyst expectations of a ₹28–55 crore profit, swinging instead to a loss. While the loss is largely due to a one-time non-cash impairment, the flat revenue growth and margin contraction from 20.4% to 16.7% signal operational headwinds in the CDMO and inhalation anesthesia segments. Expect a bearish reaction over the next 3-5 trading sessions as positional traders recalibrate valuation based on slower recovery timelines.
Piramal Pharma Ltd up for five straight sessions
▲ Bullish +0.04%
The stock is experiencing a strong technical and fundamental recovery after five days of consecutive gains, supported by a high-value strategic partnership in the high-growth Antibody-Drug Conjugate (ADC) segment. This fundamental shift, combined with a recent clean US FDA inspection and a technical upgrade from 'Strong Sell' to 'Attractive' valuation, suggests a multi-day positional trend reversal. While it faces long-term resistance at the 200-day moving average, the surge in delivery volumes and open interest indicates institutional accumulation that could sustain a swing trade toward higher recovery targets.
Get real-time alerts for PPLPHARMA
Add PPLPHARMA to your portfolio and receive instant AI-powered news alerts on your phone.
Set up free alerts →Explore More
AI Technical Analysis Alert History Other Bullish Stocks Today’s Trending